Treats thymidine kinase 2 deficiency (TK2d). Sold as Kygevvi. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 1 application for Doxecitine; Doxribtimine (sold as Kygevvi), first approved Nov 3, 2025, with 0 new uses approved and 0 published complete response letters.
| Study | Phase | Status | Posted |
|---|---|---|---|
| Doxecitin and Doxribthymine in Adult Subjects With Thymidine Kinase 2 (TK2) DeficiencyThymidine Kinase 2 (TK2 ) Deficiency, Mitochondrial Myopathies · Cristina Domínguez González | Phase 2 | Recruiting | Dec 31, 2024 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA